VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis.
Lawrence Cohen, CEO of Via Pharmaceuticals, said: “This patent is an important step in the commercial development of the compound by providing Via with exclusivity in this very large and underserved market through 2026. We are pleased with the issuance of this important patent as it further strengthens and builds on our existing intellectual property protection for our lead clinical compound.”